$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
News
News
Medical Halo Global Pharmaceutical News_Targeted Drugs_New Anti-Cancer Drugs_Overseas Medical Information_【Medical Halo Global Pharmaceutical】
瑞格非尼在胃肠道间质瘤患者中的治疗模式和疗效
2025-10-19 11:44:20
Check Details
瑞格非尼对肝细胞癌患者疗效的暴露-反应关系
2025-10-19 11:44:20
Check Details
瑞格非尼治疗转移性结直肠癌时不良事件与疗效的相关性
2025-10-19 11:44:20
Check Details
胃肠道间质瘤患者参加I期临床试验的临床结果
2025-10-19 11:44:20
Check Details
瑞格非尼在标准治疗失败后胃肠道间质瘤患者中II期临床试验的长期随访结果
2025-10-19 11:44:20
Check Details
吉非替尼治疗结直肠癌
2025-10-19 11:44:20
Check Details
转移性结直肠癌患者可服用瑞格非尼或者TAS-102
2025-10-19 11:44:20
Check Details
瑞格非尼降低治疗转移性结直肠癌死亡风险
2025-10-19 11:44:20
Check Details
结直肠癌患者服用索拉非尼发生疾病进展后可服用瑞格非尼
2025-10-19 11:44:20
Check Details
瑞戈非尼耐受性的真实数据格外重要
2025-10-19 11:44:20
Check Details
瑞戈非尼的治疗数据以及安全性
2025-10-19 11:44:20
Check Details
转移性结直肠癌服用靶向药物瑞戈非尼的临床结果
2025-10-19 11:44:20
Check Details
1
2
...
7669
7670
7671
7672
7673
7674
7675
...
10233
10234
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
Finerenone (Kerendia) for Diabetic CKD and HF with LVEF≥40%: Albuminuria, Dosing, Hyperkalemia
2
Baxdrostat (Baxfendy) for Hypertension: Aldosterone Synthase Inhibition, Dosing, and Discontinuation Rules
3
Pixclara (Floretyrosine F-18/18F-FET) Glioma PET: Distinguishing Recurrence from Treatment-Related Change
4
Adagrasib (Krazati) for KRAS G12C: NSCLC Dosing, Titration, and CRC Regulatory Update
5
Bexlutry (Lu-177 Dotatate) for SSTR-Positive GEP-NETs: PRRT Dosing and Safety Monitoring
6
Etrasimod for Ulcerative Colitis: 2mg Once Daily, Onset Timeline, and Safety Monitoring
7
Hibsago (Bepirovirsen) Japan Approval: CHB Functional Cure and B-Well Data Essentials
8
FDA Approves Isembyld (apitegromab-mstn), the World’s First Skeletal Muscle-Targeted Therapy for SMA
9
Post-Enzalutamide mCRPC: HRR/PARP, PSMA Radioligand, and Chemotherapy Sequencing
10
Ceritinib for ALK-Positive NSCLC: Indication, Dosing, and Safety Management
11
Acalabrutinib in CLL/SLL Survival Expectation: ELEVATE-TN and ASCEND Long-Term PFS, OS
12
Bosutinib for CML: Time to Response, BCR-ABL Monitoring, and Molecular Remission